Switching on the green light for chimeric antigen receptor T‐cell therapy
Open Access
- 1 January 2019
- journal article
- review article
- Published by Wiley in Clinical & Translational Immunology
- Vol. 8 (5) , e1046
Abstract
Adoptive cellular therapy involving genetic modification of T cells with chimeric antigen receptor (CAR) transgene offers a promising strategy to broaden the efficacy of this approach for the effective treatment of cancer. Although remarkable antitumor responses have been observed following CAR T‐cell therapy in a subset of B‐cell malignancies, this has yet to be extended in the context of solid cancers. A number of promising strategies involving reprogramming the tumor microenvironment, increasing the specificity and safety of gene‐modified T cells and harnessing the endogenous immune response have been tested in preclinical models that may have a significant impact in patients with solid cancers. This review will discuss these exciting new developments and the challenges that must be overcome to deliver a more sustained and potent therapeutic response.Keywords
Funding Information
- National Health and Medical Research Council (APP1062580, APP1132373)
- Cancer Council Victoria (APP1143517)
- National Breast Cancer Foundation (ECF‐17‐005)
- National Health and Medical Research Council (APP1136680)
This publication has 139 references indexed in Scilit:
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in GlioblastomaMolecular Therapy, 2013
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer ImmunotherapyMolecular Therapy Nucleic Acids, 2013
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- Oncolytic Virus-initiated Protective Immunity Against Prostate CancerMolecular Therapy, 2011
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Signaling Through OX40 Enhances Antitumor ImmunitySeminars in Oncology, 2010
- An Improved Bicistronic CD20/tCD34 Vector for Efficient Purification and In Vivo Depletion of Gene-Modified T Cells for Adoptive ImmunotherapyMolecular Therapy, 2010
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safetyLeukemia, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010